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ﬁnd biomarkers for BrS diagnosis and to investigate possible mecha-
nism of BrS, we conducted this study.
METHODS Twenty-ﬁve control patients, 25 BrS patients without
SCN5A mutations and 20 BrS patients with SCN5A mutations were
included in this study. Blood samples were collected in BD Vacutainer
9NC 0.129M (BD Biosciences). White blood cells were separated using
Lympholyte-H sterile liquid. Total RNA was isolated by using Trizol
(Life Technologies) and Direct-Zol RNA MiniPrep Kit and was
reverse transcribed with QuatntiTect Reverse Transcription Kit (Qia-
gen). Real-time quantitative PCR (Q-PCR) analysis was performed
using 7500-Fast Real-Time PCR Systems with MESP1 speciﬁc primers
and probes and TaqMan Gene Expression Master Mix (Life Tech-
nologies). MESP1 expression level was normalized by GAPDH. Differ-
ences between the groups were examined by one way ANOVA and
t-tests. Results with p <0.05 were considered statistically signiﬁcant
in all analyses.
RESULTS Among 5 cardiac speciﬁc transcription factors tested, MESP1
is one of the two expressed in white blood cells (WBC). WBC levels of
MESP1 were signiﬁcantly lower in BrS patients than that in normal
control group (1.080.8 in control group vs. 0.660.38 in BrS patients
without SCN5A mutation, 0.440.42 in BrS patients with SCN5A
mutation respectively, P ¼0.001 by ANOVA analysis). T-tests revealed
that the difference between control group, BrS group without SCN5A
mutation and BrS group with SCN5A mutation is statistically signiﬁ-
cant (P ¼0.012 and P¼0.000 respectively). Nevertheless, there was no
difference detected between the two BrS groups (P¼0.215). The area
under the Receiver Operating Characteristics analysis (ROC) curve for
prediction of BrS using MESP1 levels is 0.775 (95% CI 0.668, 0.882,
asymptotic Sig.¼0.000). At the optimal cutoff, the corresponding
maximum sensitivity and speciﬁcity were 0.62 (95% CI: 0.47, 0.76)
and 0.88 (0.69, 0.97), respectively.
CONCLUSIONS MESP1 is a major cardiac speciﬁc transcription factor
that expresses in white blood cells. Patients with BrS have reduced
circulating MESP1. Our results suggest that assessment of circulating
MESP1 may be used as a biomarker for BrS diagnosis. Our results also
suggest that decreased expression of MESP1 may be one of patho-
physiological mechanism of BrS.GW26-e5401
The effect of atorvastatin on endogenous H2S formation in red blood cell
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OBJECTIVES To conﬁrm whether can atorvastatin affect the level of
H2S in plasma through the observation on atherosclerosis model of
rabbits, to assess whether atorvastatin can affect the formation of H2S
from erythrocytes. We would like to know more about the mechanism
of the effect of statins on endogenous H2S formation, for providing
new ideas of variant of H2S-directed pharmacotherapy.
METHODS We chose 36 male Japanese big ear rabbits and divide
into 3 groups randomly, including normal group, high-fat-fed
without medicine group(control group) and high-fat-fed with medi-
cine group(statin group). 12 rabbits in the normal group are given
normal diet. Others 24 rabbits are given high fat diet for 12 weeks.
Rabbits in statin group are given atorvastatin 20mg everyday for 8
weeks (13 to 20 weeks). Determinating the level of H2S and MPST
from erythrocytes and the level of H2S in plasma to examine
mechanism of the effect of statins on endogenous H2S formation.
We measure the level of H2S in plasma by sensitive sulphur elec-
trode assay, measure MPST by western blotting. According to the
principle of MPST enzyme catalytic reaction, we measure the level
of H2S from erythrocytes.
RESULTS The level of H2S released from erythrocytes in high-fat-fed
group was signiﬁcant higher than normal group (p <0.05). There were
little differences in the level of H2S in red blood cell among each group
after 8 weeks (p >0.05). The level of H2S released from erythrocytes
in normal group had no changes before and after observation, but it
reduced remarkably in high-fat-fed without medicine group after
observing 8 weeks (p<0.05), it had little changes in high-fat-fed with
medicine group after taking atorvastatin 8 weeks (P >0.05). MPST
expression in erythrocytes were resemblance among each group
(p >0.05). The level of H2S in plasma in high-fat-fed without medicine
group was signiﬁcant lower than normal group (p <0.05). It was
obviously higher in high-fat-fed with medicine group than in high-
fat-fed without medicine group (p <0.05). The level of H2S in plasma
in high-fat-fed with medicine group was lower than normal group,
but no statistical difference (p >0.05).CONCLUSIONS Atorvastatin increase net H2S production by inhibit-
ing its mitochondrial oxidation and reducing CoQ concentration.
However atorvastatin can not affect the formation of endogenous H2S
released from erythrocytes depended mainly on MPST pathway.
Therefore atorvastatin can not affect endogenous H2S formation in red
blood cell.
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OBJECTIVES Glycated albumin (GA) and the endogenous secretory
receptor for advanced glycation endproducts (esRAGE) may modulate
risk related to atherosclerosis. We tested the hypothesis that elevated
GA and reduced esRAGE in serum are associated with adverse clinical
outcomes in patients with type 2 diabetes and stable coronary artery
disease (CAD).
METHODS We determined GA and esRAGE serum levels in 576
consecutive patients with type 2 diabetes and stable CAD undergoing
sirolimus-eluting stent (SES)-PCI. The primary endpoint was the
incidence of major adverse cardio-cerebral events (MACCE) including
cardiac death, non-fatal myocardial infarction, and non-fatal stroke
during a 2-year follow-up. The secondary endpoint was the occur-
rence of clinically driven repeat revascularization during a 2-year
follow-up. The prognostic value of GA and esRAGE was determined
with the Cox-proportional hazards model after adjustment for
covariates.
RESULTS A total 40 patients (6.9%) experienced MACCE, and 108
(18.8%) patients underwent repeat coronary revascularization during
the follow-up. Serum GA levels correlated positively (both p<0.001),
while serum esRAGE levels negatively (both p<0.05), with the pri-
mary and secondary endpoints, respectively. Serum GA (HR¼1.220,
95% CI 1.160-1.283; HR¼1.152, 95% CI 1.113-1.191, respectively; both
p<0.001) and esRAGE (HR¼0.597, 95% CI 0.407-0.874; HR¼0.751, 95%
CI 0.613-0.919, respectively; both p<0.01) levels remained indepen-
dent predictors of the primary and secondary endpoints after
adjustment for possible confounders.
CONCLUSIONS Serum GA and esRAGE are novel predictors of long-
term clinical outcomes in patients with type 2 diabetes and stable
CAD. Increased serum GA and decreased esRAGE are associated with a
poor prognosis in such patients.
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OBJECTIVES Pre-clinical studies have shown that hypoxia pre-
conditioning can enhance stem cell therapeutic potential for
myocardial repair. We sought to investigate the safety and feasibility
of intracoronary administration of hypoxia-preconditioned bone
marrow cells (HP-BMCs) for acute ST segment elevation myocardial
infarction (STEMI).
METHODS We randomized 22 patients with acute STEMI to receive
intracoronary administration of normoxia BMCs (N-BMCs) (n¼11) or
HP-BMCs (n¼11) following successful revascularization. Another
14 patients were recruited as the control (n¼14).
